Synaptogenix Inc SNPX

NAS: SNPX | ISIN: US87167T2015   17/05/2024
4,750 USD (-3,26%)
(-3,26%)   17/05/2024

7 mei 2024 · Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery · Persbericht

24 april 2024 · Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing · Persbericht

9 april 2024 · Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics · Persbericht

3 april 2024 · Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing · Persbericht

19 december 2023 · Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders · Persbericht

6 december 2023 · Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's · Persbericht

2 november 2023 · Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology · Persbericht

26 september 2023 · Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease · Persbericht

7 september 2023 · Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study · Persbericht

19 juli 2023 · Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis · Persbericht

13 juli 2023 · Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience · Persbericht

7 maart 2023 · Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities · Persbericht

16 december 2022 · Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease · Persbericht

18 november 2022 · Synaptogenix Announces $15 Million Private Placement with Existing Investors · Persbericht

19 oktober 2022 · Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022 · Persbericht

28 september 2022 · Synaptogenix Welcomes Lecanemab Phase 3 Trial Results · Persbericht

12 augustus 2022 · Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network · Persbericht

26 juli 2022 · Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data · Persbericht

21 juli 2022 · Synaptogenix Announces Corporate Update Conference Call · Persbericht

20 juli 2022 · Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data · Persbericht

Mijn selecties